TLTFF – Share Interest Spurred by Theralase’s State-of-the-Art Lasers for the Treatment of Chronic Pain

bullquake Newsletter

*TLTFF – Share Interest Spurred by Theralase`s State-of-the-Art Lasers for the Treatment of Chronic Pain*

——————– [LINK: http://www.facebook.com/people/BullQuake-Stocks/100000308486725] [IMG: facebook] [LINK: https://twitter.com/BullQuake] [IMG: twitter] www.BullQuake.com Recent Winners:CYTR 208%, ATHX Over 55%, DRRX 15% Stocks on Watch: NAVB, CREE, ETRM, ELED, IENT, HCTI****

**

Toronto, Ontario–(Newsfile Corp. – April 15, 2014) – Roger Dumoulin-White, P. Eng, President and CEO for [LINK: http://www.theralase.com/] Theralase Technologies Inc.(TSXV: TLT) (OTC: TLTFF) (`Theralase`) speaks to Tracy Weslosky, Editor-in-Chief and Publisher of InvestorIntel about Theralase`s state-of-the-art patented laser equipment for biostimulative and biodestructive clinical applications to treat chronic pain. Theralase`s shares haves been performing well and Roger explains that this should be no surprise because “our technology speaks for itself. It`s patented technology; it`s state of the art and it`s addressing an unmet need in the industry and in the medical world. There`s a one hundred billion dollar pain market in the US, which is what our therapeutic is gauged for and the bladder cancer market we`re going into is a four billion dollar unmet need.” Theralase has high demand technology applications already available to the market such as the TLC 1000 series: “it`s a best in-class technology, able to penetrate four inches into tissue. So, we can target tissue, target pain, we can target inflammation and accelerate tissue healing the advancements that we want to make.” However, Theralase plans to introduce a more advanced technology in the fourth quarter of 2014. The main advancement is that the light will be monitored; giving the operator a reading of exactly how deep it is reaching and how much energy is deposited at that depth. This means the equipment can be tailored or calibrated for a variety of conditions and patients: “We know exactly how deep the light is going and how much light; therefore, the new technology is very patient specific; as we all know individuals and their conditions are different.” Theralase`s current line of technology aims to heal tissue, from humans to animals. Some of its patented technology is also used in oncology and bacterial destruction.

**

[LINK: https://www.youtube.com/watchfeature=player_embedded&v=CX94YjcEjxE] Share interest spurred by Theralase`s state-of-the-art lasers for the treatment of chronic pain Roger explains that the main conditions targeted by the technology are neuro-muscular-skeletal; this implies such things as sport injuries, wound healing, geriatric conditions such as arthritis or chronic pain problems. The reason that the technology has such reach as to be suitable for humans and animals such as horses, cats, dogs or dolphins is that “mammalian tissue is all the same.” So, Theralase`s technology works by injecting light harmlessly into tissue; the light is absorbed by proteins in tissue cells and transformed into biochemical energy, which the cells then use to heal themselves in half the normal time. So, all tissue types can be treated as well as all injury types, regardless of severity.

Theralase, meanwhile, has a number of benchmarks and targets in the near future, which have been getting attention from investors. Roger explains that Theralase`s technology “is best-in-class in the sense that it can reach down four inches of tissue, but what happens is that patients` physical characteristics change; they have different skin colorations different levels of subcutaneous fat and muscle and it all affects the propagation of light through tissue. So all the technology on the market today has no way of determining how deep that light is going… Our new technology takes into account all that variability because it can determine, regardless of the patient, how deep the light is going,” such that it can deliver the exact dose of energy or light required. Roger adds that “we`ve discovered that light is a drug.

If you put too little, you don`t get an effect. If you put too much you don`t get a good effect; it is very similar to pharmaceutical drugs, such as aspirin: if you took a tenth of an aspirin, it`s not going to cure your headache and if you took 200 aspirins you would end up going to the emergency room.” So, it is the same thing with light; a certain amount is needed to obtain the desired results and that is what Theralase`s technology will achieve later in 2014. As for the all-important bottom line, Theralase has been selling in the CAD$ 1-2 million range in Ontario, but it is expanding into Western Canada and in a more significant way in the much larger US market: “with this new technology we`re going into a recurring revenue model. We have about 1200 systems in the field now of our existing technology; we plan to trade them up to our new technology.” The doctors, therapists and chiropractors who use Theralase generate on average around ten thousand dollars a month. Theralase plans to rent the new technology to healthcare professionals for about 500 dollars a month, “so they would take home 95% of the revenue and in that model it allows us to provide them with warranty, marketing, clinical support, technical support to partner in their business, for as long as they have the equipment. Under that type of model, for every thousand units that we place in the field, we will be generating five hundred thousand dollars a month of mostly profit.” *About BullQuake.com:*

BullQuake.com is a leader in small cap investor research with over a decade of experience in managing assets, trading, research, and technical analysis.

*Follow BullQuake.com on Twitter*https://twitter.com/bullquake *Follow BullQuake.com on Facebook*https://www.facebook.com/bullquake.stocks Sign up for the free investor news and stock alerts at BullQuake.com http://www.BullQuake.com *Download one of our application:*

*The Stock Quotes & Charts App at*https://play.google.com/store/apps/detailsid=com.StockQuote#t=W251bGwsMSwxLDIxMiwiY29tLlN0b2NrUXVvdGUiXQ..

*The Stock Alerts App at*https://play.google.com/store/apps/detailsid=com.BullQuake&hl=en Disclaimer/ Disclosure: BullQuake.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BullQuake.com has not been compensated for any stocks mentioned in this newsletter for either news publication, dissemination and profile on BullQuake.com and partnering websites. BullQuake.com currently does not hold a position in any stocks mentioned in this newsletter.

——————– DISCLAIMER – This disclaimer is to be read and fully understood before using our site, services, or joining any of our network sitesFacebook, Twitter, Partnering Sites, joining our email list, or subscribing to our text message alerts. BullQuake Marketing LLC, BullQuake.com or its employees are not registered Investment Advisers. Through use of this website viewing or using you agree to hold BullQuake.com its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. BullQuake Marketing LLC is not liable for any investment decisions by its viewers and or subscribers. It is highly recommended that BullQuake.coms viewers and or subscribers speak with a financial adviser, or a broker-dealer before making any investment decisions. BullQuake.com is written and published by BullQuake Marketing LLC, its owner and employees. Readers are advised that all content and information listed on Bullquake.com or provided to you from BullQuake Marketing LLC or its employees is issued solely for informational purposes. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation to buy or sell any securities. BullQuake.com is owned and operated by BullQuake Marketing LLC. BullQuake Marketing LLC engaged in the business of advertising and promoting companies for monetary compensation. Any compensation received by BullQuake Marketing LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. BullQuake Marketing LLC has not been compensated for any stocks mentioned in this newsletter. Anyone viewing this newsletter should assume the hiring party or affiliates of the hiring party own shares of said companies of which they plan to liquidate, further understanding that the liquidation of those shares may or may not negatively impact the share price. BullQuake Marketing LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. BullQuake.coms sponsored advertisements do not purport to provide an analysis of any companys financial position, operations or prospects and this is not to be construed as a recommendation by BullQuake.com or an offer or solicitation to buy or sell any security. Neither the owner of BullQuake.com nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Any opinions expressed are subject to change without notice. BullQuake.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, through their website or is available from public sources and BullQuake.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. BullQuake.com does not independently investigate the information. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewers entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit www.BullQuake.com. BullQuake.com makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors.

*BullQuake.com*

P.O. Box 795 200 S WAYNE AVE| Waynesboro, Virginia22980| USA ———————————————————————

Related posts:

1. $TLTFF – Destroying Cancer with Light, TLTFF Theralase Technologies Inc
2. $TLTFF – Keep a Close Watch on This One
3. $TLTFF – News – Theralase Technologies Inc. (TLTFF-OTCBB) (TLT.V) is Advancing on its Sales and Marketing Mandate
4. TLTFF_–_Closed_up_3.66%,_Solid_Base_with_Upcoming_Catal
5. Hot_DD,_Recaps_and_Catalysts_–_ETRM,_HCTI,_NVGT,_RGDX